Indexed keywords
EVEROLIMUS;
KALLIKREIN;
KALLIKREIN 10;
KALLIKREIN 6;
TUMOR MARKER;
UNCLASSIFIED DRUG;
KLK10 PROTEIN, HUMAN;
KLK6 PROTEIN, HUMAN;
ARTICLE;
CANCER PATIENT;
CANCER PROGNOSIS;
CANCER REGRESSION;
CANCER THERAPY;
DNA REPAIR;
EXOME;
GENE;
GENE MUTATION;
GENOME;
GENOTYPE;
HUMAN;
MONITORING;
PANCREAS CANCER;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
BLOOD;
PANCREAS TUMOR;
HUMANS;
KALLIKREINS;
PANCREATIC NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
1
84876305008
Rare cancer successes spawn 'exceptional' research efforts
Kaiser J. Rare cancer successes spawn 'exceptional' research efforts. Science 2013;340:263.
(2013)
Science , vol.340
, pp. 263
Kaiser, J.1
2
84867333656
Genome sequencing identifies a basis for everolimus sensitivity
Lyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
(2012)
Science , vol.338
, pp. 221
Lyer, G.1
Hanrahan, A.J.2
Milowsky, M.I.3
Al-Ahmadie, H.4
Scott, S.N.5
Janakiraman, M.6
3
84884153333
Power of rare diseases: Found in translation
Fishman MC. Power of rare diseases: found in translation. Science Transl Med 2013;5:201ps11.
(2013)
Science Transl Med , vol.5
Fishman, M.C.1
4
77957833984
Cancer biomarkers: Can we turn recent failures into success?
Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-7.
(2010)
J Natl Cancer Inst , vol.102
, pp. 1462-1467
Diamandis, E.P.1
5
1542378202
Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems
Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6. (Pubitemid 38351297)
(2004)
Journal of the National Cancer Institute , vol.96
, Issue.5
, pp. 353-356
Diamandis, E.P.1
6
84864697164
The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem?
Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med 2012;10:87.
(2012)
BMC Med , vol.10
, pp. 87
Diamandis, E.P.1
7
80054943335
Why have protein biomarkers not reached the clinic?
Hanash SM. Why have protein biomarkers not reached the clinic? Genome Med 2011;3:66.
(2011)
Genome Med , vol.3
, pp. 66
Hanash, S.M.1
8
78651401851
Cancer trial errors revealed
Reich ES. Cancer trial errors revealed. Nature 2011;469: 139-40.
(2011)
Nature , vol.469
, pp. 139-140
Reich, E.S.1
9
84874603174
More data please!
Baggerly K. More data please! Clin Chem 2013;59: 459-61.
(2013)
Clin Chem , vol.59
, pp. 459-461
Baggerly, K.1
10
36348936853
POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma?
DOI 10.1016/j.clinbiochem.2007.09.003, PII S000991200700358X
Diamandis EP. POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma? Clin Biochem 2007;40:1437-9. (Pubitemid 350151427)
(2007)
Clinical Biochemistry , vol.40
, Issue.18
, pp. 1437-1439
Diamandis, E.P.1
11
0042367739
Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics?
DOI 10.1373/49.8.1272
Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-5. (Pubitemid 36900611)
(2003)
Clinical Chemistry , vol.49
, Issue.8
, pp. 1272-1275
Diamandis, E.P.1
12
84861690041
Medicine. The ultimate genetic test
Drmanac R. Medicine. The ultimate genetic test. Science 2012;336:1110-2.
(2012)
Science , vol.336
, pp. 1110-1112
Drmanac, R.1
